Press Release: Sanofi completes the acquisition of Dynavax

Core Insights - Sanofi has completed the acquisition of Dynavax Technologies Corporation, enhancing its portfolio in adult immunization with Dynavax's hepatitis B vaccine HEPLISAV-B and shingles vaccine candidate Z-1018 [1][2] Acquisition Details - The tender offer for Dynavax's common stock expired on February 9, 2026, and all conditions were satisfied, leading to Sanofi's acceptance of the shares [3] - The acquisition was finalized through a merger, with Dynavax becoming a wholly owned subsidiary of Sanofi, and shares not tendered in the offer will receive $15.50 per share in cash [4] Strategic Implications - This acquisition strengthens Sanofi's commercial reach and development capabilities in the vaccine market, positioning the company for growth in adult immunization [2]